voxilaprevir-velpatasvir-sofosbuvir
Selected indexed studies
- Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (J Hepatol, 2021) [PMID:33220331]
- Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (Clin Gastroenterol Hepatol, 2021) [PMID:31706062]
- Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. (JHEP Rep, 2024) [PMID:38357421]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (2021) pubmed
- Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2021) pubmed
- Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. (2024) pubmed
- Treatment failure with DAA therapy: Importance of resistance. (2021) pubmed